💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sotatercept

CHEMBL1743073 Phase 4 승인됨 Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Sotatercept is a fusion protein consisting of the extracellular domain of activin receptor type IIA (ActRIIA) fused to the Fc region of human IgG1, acting as a ligand trap for TGF-beta superfamily members including activin A, to treat pulmonary arterial hypertension. By sequestering hyperactivated TGF-beta/activin signaling, it counteracts pulmonary vascular smooth muscle cell proliferation and vascular remodeling in PAH. Clinical trials demonstrated significant improvements in exercise capacity and hemodynamics in PAH patients.

치료 영역

Bladder Cancer Osteoporosis Hypertension Leukemia

작용 기전

Engineered protein combining domains from two different proteins to achieve enhanced therapeutic activity, often linking a receptor-binding domain with an immunoglobulin Fc region for extended half-life.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Engineered protein combining domains from two different proteins to achieve enhanced therapeutic activity, often linking a receptor-binding domain with an immunoglobulin Fc region for extended half-life.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

Sotatercept is a fusion protein consisting of the extracellular domain of activin receptor type IIA (ActRIIA) fused to the Fc region of human IgG1, acting as a ligand trap for TGF-beta superfamily members including activin A, to treat pulmonary arterial hypertension. By sequestering hyperactivated TGF-beta/activin signaling, it counteracts pulmonary vascular smooth muscle cell proliferation and vascular remodeling in PAH. Clinical trials demonstrated significant improvements in exercise capacity and hemodynamics in PAH patients.

Engineered protein combining domains from two different proteins to achieve enhanced therapeutic activity, often linking a receptor-binding domain with an immunoglobulin Fc region for extended half-life.

Yes, Sotatercept is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1743073. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.